Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.76 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.48 |
| ▸ | CTSD | P07339 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136911 | 0.92 | BACE1 (0.89) | BACE1BACE2CTSD | |
| SCHEMBL4141578 | 0.87 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL21067614 | 0.87 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL13879668 | 0.82 | BACE1 (0.82) | BACE1BACE2CTSD | |
| Hydrochloric Acid SCHEMBL4286079 | 0.82 | BACE1 (0.81) | BACE1BACE2CTSD | |
| SCHEMBL4146578 | 0.80 | BACE1 (0.87) | BACE1BACE2 | |
| SCHEMBL4135087 | 0.80 | BACE1 (0.75) | BACE1 | |
| SCHEMBL4147959 | 0.80 | BACE1 (0.75) | BACE1 | |
| SCHEMBL4518090 | 0.80 | BACE1 (0.85) | BACE1BACE2CTSD | |
| Hydrochloric Acid SCHEMBL4522370 | 0.79 | BACE1 (0.83) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023762-A1 | Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | claimed |
| EP-1966160-A1 | SUBSTITUTED 2-AMINOPYRIMIDINE-4-ONES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF Aß-RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | claimed |
| WO-2007073284-A1 | SUBSTITUTED 2-AMINOPYRIMIDINE-4-ONES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF Aß-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | claimed |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| US-20090023762-A1 | Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023762-A1 | Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023762-A1 | Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1966160-A1 | SUBSTITUTED 2-AMINOPYRIMIDINE-4-ONES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF Aß-RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007073284-A1 | SUBSTITUTED 2-AMINOPYRIMIDINE-4-ONES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF Aß-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007073284-A1 | SUBSTITUTED 2-AMINOPYRIMIDINE-4-ONES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF Aß-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023762-A1 | Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies | PSEN2, PSEN1, MAPT | BACE1 5/4885BACE2 12/4885CTSD 4068/4885 |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | TNNI3, TNNT2, TNNC1 | BACE1 5/4885BACE2 12/4885CTSD 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.